Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph not_applicable
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

active_not_recruiting3100%

Recent Activity

3 active trials
Showing 3 of 3
active_not_recruitingnot_applicable

An Integrated Genomic Approach to Assess Genetic Risk and Drug Sensitivity

NCT07555639
active_not_recruitingnot_applicable

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

NCT04905082
active_not_recruitingnot_applicable

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

NCT05455606

Clinical Trials (3)

Showing 3 of 3 trials
NCT07555639Not Applicable

An Integrated Genomic Approach to Assess Genetic Risk and Drug Sensitivity

Active Not Recruiting
NCT04905082Not Applicable

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

Active Not Recruiting
NCT05455606Not Applicable

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type
GENETIC
Total Trials
3